MT 2002 - Macrophage Therapeutics
Alternative Names: MT-2000 class; MT-2002 - Macrophage TherapeuticsLatest Information Update: 19 Jul 2024
At a glance
- Originator Macrophage Therapeutics
- Class Anti-inflammatories; Drug conjugates; Steroids
- Mechanism of Action Macrophage modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation
Most Recent Events
- 08 Jul 2024 Preclinical trials in Inflammation in USA (unspecified route) prior to July 2024 (Macrophage Therapeutics pipeline, July 2024)